Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $9
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $10 to $9.
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $10 to $9.